Bristol-Myers Squibb, CHECKMATE-76K, FDA, melanoma, Opdivo
Nivolumab is approved by the FDA for adjuvant treatment of Stage IIB/C melanoma
Nov 2023: Nivolumab (Opdivo, Bristol-Myers Squibb Company) was granted approval by the Food and Drug Administration as an adjuvant therapy for Stage IIB/C melanoma in patients 12 years of age and older who had undergone complete..
Bristol Myers Squibb, CHECKMATE-648, esophageal squamous cell carcinoma, NCT03143153, nivolumab, Opdivo, Yervoy
Opdivo in combination with chemotherapy and Opdivo in combination with Yervoy is approved by FDA for first-line esophageal squamous cell carcinoma indications
June 2022: For the first-line therapy of individuals with advanced or metastatic esophageal squamous cell carcinoma (ESCC), the Food and Drug Administration has approved the following:In combination with fluoropyrimidine- and pla..
BMS, CHECKMATE-816, nivolumab, NSCLC, Opdivo
Neoadjuvant nivolumab and platinum-doublet chemotherapy is approved for early-stage non-small cell lung cancer
March 2022: In the neoadjuvant setting, the FDA approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer (NSCLC).Thi..
Bristol Myers Squibb, CHECKMATE-274, nivolumab, Opdivo, Urothelial carcinoma
Nivolumab has been approved by the FDA for use as an adjuvant treatment for urothelial carcinoma
August 2021: Nivolumab (Opdivo, Bristol-Myers Squibb Co.) has been approved by the Food and Drug Administration for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence following rad..
Bristol Myers Squibb, CHECKMATE-649, fluoropyrimidine, nivolumab, Opdivo, platinum-containing chemotherapy
Nivolumab in addition to chemotherapy is approved by FDA for metastatic gastric cancer and esophageal adenocarcinoma
August 2021: For advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in conjunction wit..